Chemotherapy With Pemetrexed in Combination With Platinum for Advanced Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
This is a two-arm, parallel, open-label, Phase 2 multicenter study of pemetrexed as first
line combination therapy with either cisplatin or carboplatin in the palliative setting of
stage IIIb and IV non-small cell lung cancer patients. Approximately 130 patients will be
included in about 15 centers in Germany and randomized to one of the above treatment regimens
in a 1:1 ratio. Chemotherapy will be administered over a maximum of six cycles with a
standard length of 21 days. Primary objective will be the Progression Free Survival Time of
patients as assessed in both treatment arms.